CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Core Insights - CervoMed Inc. has released additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies, indicating potential efficacy in slowing disease progression [1] Trial Results - The final analyses of the RewinD-LB trial were conducted after the August 2025 database lock, covering a total of 48 weeks, which included a 16-week placebo-controlled phase followed by a 32-week neflamapimod-only extension phase [1] - In participants with plasma ptau181 levels below 21 pg/mL, there was a trend towards improvement with NFMD/A compared to placebo during the initial phase [2] - NFMD/B showed significant improvement over NFMD/A on the Clinical Dementia Rating Sum of Boxes (CDR-SB) with a change of −0.58 (p=0.024) during the first 16 weeks of the extension phase [3] - Transitioning from placebo to NFMD/B resulted in significant improvements in CDR-SB and ADCS-CGIC scores over respective 16-week periods [4] - NFMD/B reduced the risk of clinically meaningful progression by 67% compared to NFMD/A over 32 weeks and by 75% compared to placebo over 16 weeks [4] Biomarker Analysis - New analyses of plasma glial fibrillary acidic protein (GFAP) indicated that participants transitioning from placebo to NMFD/B experienced a significant reduction in plasma GFAP levels, estimated at 50% lower than during the placebo treatment [5] - In participants with low likelihood of Alzheimer's disease co-pathology, changes in plasma GFAP significantly correlated with changes in CDR-SB scores, indicating that reductions in GFAP were associated with lower dementia severity [6] Market Reaction - Following the announcement, CervoMed shares increased by 7.97% to $9.21, with an intraday high of $9.30 and a low of $8.64, although the stock remains 45.6% below its 52-week high [7]